Triveni Bio Overview

  • Year Founded
  • 2019

Year Founded

  • Status
  • Private

  • Employees
  • 45

Employees

  • Latest Deal Type
  • Series C

  • Latest Deal Amount
  • $65M

  • Investors
  • 14

Triveni Bio General Information

Description

Operator of a clinical-stage biotechnology company designed to create antibody-based therapies targeting immunological and inflammatory diseases. The company offers a genetics-informed antibody discovery and engineering platform, deep insights from human genetic data, and biologics targeting validated disease mechanisms, enabling patients and clinicians dealing with immune and inflammatory disorders to access potentially more effective and precise treatments.

Contact Information

Website
www.triveni.bio
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 99 Coolidge Avenue
  • Suite 450
  • Watertown, MA 02472
  • United States
+1 (800)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 99 Coolidge Avenue
  • Suite 450
  • Watertown, MA 02472
  • United States
+1 (800)

Triveni Bio Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Triveni Bio Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Later Stage VC (Series C) 17-Jun-2026 $65M Completed Clinical Trials - Phase 2
3. Later Stage VC (Series B) 18-Jun-2025 Completed Pre-Clinical Trials
2. Early Stage VC (Series A) 26-Oct-2023 $91.6M $117M Completed Startup
1. Seed Round $25M $25M Completed Startup
To view Triveni Bio’s complete valuation and funding history, request access »

Triveni Bio Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series C
Series B
Series A-2
Series A-1
Seed-3
Seed-2 6,676,725 $0.000010 $1.5 $1.5 1x $1.5 1.75%
Seed-1 1,000,000 $0.000010 $0.4 $0.4 1x $0.4 0.26%
To view Triveni Bio’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Triveni Bio Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of a clinical-stage biotechnology company designed to create antibody-based therapies targeting immunological a
Drug Discovery
Watertown, MA
45 As of 2025

Madison, WI
 

New York, NY
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Triveni Bio Competitors (60)

One of Triveni Bio’s 60 competitors is Centrose, a Venture Capital-Backed company based in Madison, WI.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Centrose Venture Capital-Backed Madison, WI
Xalud Therapeutics Venture Capital-Backed New York, NY
Seismic Therapeutic Venture Capital-Backed Watertown, MA
Aviceda Therapeutics Venture Capital-Backed Cambridge, MA
Inovio Pharmaceuticals Corporation Plymouth Meeting, PA
You’re viewing 5 of 60 competitors. Get the full list »

Triveni Bio Patents

Triveni Bio Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026151944-A1 Anti-il-13 antibodies and uses thereof Pending 10-Jan-2025
WO-2026151948-A1 Anti-il-13 antibodies and uses thereof Pending 10-Jan-2025
WO-2026151954-A1 Klk5/7 + il-13 targeting antibodies and uses thereof Pending 10-Jan-2025
WO-2026085370-A2 Dual inhibitor trypsin antibodies and uses thereof Pending 16-Oct-2024
WO-2026085370-A3 Dual inhibitor trypsin antibodies and uses thereof Pending 16-Oct-2024 C07K16/40
To view Triveni Bio’s complete patent history, request access »

Triveni Bio Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Triveni Bio Investors (14)

Investor Name Investor Type Holding Investor Since Participating Rounds
Ascenta Capital Venture Capital Minority
Janus Henderson Investors Asset Manager Minority
Deep Track Capital Venture Capital Minority
Fidelity Management & Research Company Asset Manager Minority
Goldman Sachs Asset Management Asset Manager Minority
You’re viewing 5 of 14 investors. Get the full list »

Triveni Bio Acquisitions (1)

Triveni Bio’s most recent deal was a Merger/Acquisition with Amagma Therapeutics. The deal was made on 26-Nov-2023.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Amagma Therapeutics 26-Nov-2023 Merger/Acquisition Drug Discovery
To view Triveni Bio’s complete acquisitions history, request access »

Triveni Bio FAQs

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process